Lundbeck/Otsuka Global Alliance Will Support Lundbeck's Move Into U.S. Psychiatry Market
This article was originally published in The Pink Sheet Daily
Two firms will collaborate on the development and marketing of new psychiatric products, including an intramuscular depot formulation of the blockbuster antipsychotic medicineLundbeck Inc. , Abilify.
You may also be interested in...
Of 34 deals in the psychiatric disorder space since 2008, none have been mergers and acquisitions, but two-thirds of such transactions have involved licensing of compounds before regulatory approval. The major deals in the space have been a multi-compound collaboration between Otsuka and Lundbeck and the failed tie-up between AstraZeneca and Targacept.
Pfizer top management hasn’t yet decided whether it will divide in two or stop at a “virtual split.” Plus updates on Lundbeck/Otsuka, Shire/SARcode, AstraZeneca/Actavis, and more.
The Japanese company and its Danish partner garnered FDA approval for the long-acting injectable form of the blockbuster antipsychotic Abilify – the first approval of the five compounds the companies are partnered on.